Peritoneal Metastases Clinical Trial
Official title:
Preoperative Inspiratory Muscle Training for Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy - a Feasibility Study
Verified date | December 2022 |
Source | Uppsala University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this randomized controlled feasibility study was to evaluate the feasibility of preoperative inspiratory muscle training in patients undergoing surgery because of peritoneal metastases. The main questions it aimed to answer was how feasible the intervention is regarding process and scientific feasibility as defined by Thabane et al 2010. Participants in the intervention group were using a handheld device to increase their inspiratory muscle strength prior to surgery and researchers compared this group to a control group who were offered a sham treatment.
Status | Completed |
Enrollment | 30 |
Est. completion date | September 2020 |
Est. primary completion date | September 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Scheduled for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy Exclusion Criteria: - Surgery scheduled less than two weeks from the date of inclusion - Inability to speak and understand Swedish |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Uppsala University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility of preoperative inspiratory muscle training | Feasibility will be assessed using two domains: process and scientific feasibility. These domains include several parts such as recruitment rates, time available for training, intervention adherence, patient acceptability, pre-and postoperative respiratory muscle and lung function assessments, reproducibility of assessments, preliminary treatment effect, incidence of PPCs, and adverse events. | The different outcome measures are assessed continuously during a period from inclusion until discharge from the hospital. This period varied in length (3 weeks-3 months) depending on when participants were scheduled for surgery. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03422432 -
Prophylactic HIPEC for Colorectal Cancers at High Risk of Developing Peritoneal Metastases
|
N/A | |
Not yet recruiting |
NCT06295094 -
The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.
|
Phase 2 | |
Recruiting |
NCT05056389 -
Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA)
|
Phase 1 | |
Withdrawn |
NCT03682744 -
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
|
Phase 1 | |
Recruiting |
NCT06367270 -
The Application of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Surface Malignancies
|
Phase 2 | |
Recruiting |
NCT05623787 -
Diagnostic Value of Diffusion-weighted Magnetic Resonance in High-risk Colorectal and Appendiceal Neoplasms
|
N/A | |
Not yet recruiting |
NCT05095467 -
HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction
|
Phase 2 | |
Completed |
NCT04083547 -
Circulating Tumour Cells in Patients With Peritoneal Metastases
|
||
Recruiting |
NCT06216561 -
Intraperitoneal LSTA1 in CRS-HIPEC
|
Phase 1 | |
Recruiting |
NCT05277766 -
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer
|
Phase 1 | |
Not yet recruiting |
NCT05318794 -
Neoadjuvant Systemic and Peritoneal Chemotherapy for Advanced Gastric Cancer
|
Phase 2 | |
Terminated |
NCT05581719 -
A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy
|
Phase 1/Phase 2 | |
Recruiting |
NCT05379790 -
Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin
|
Phase 1 | |
Recruiting |
NCT05204173 -
Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis
|
Phase 2 | |
Recruiting |
NCT04956068 -
PIPAC for Peritoneal Metastases
|
Phase 1 | |
Recruiting |
NCT04861558 -
Efficacy of Hyperthermic Intraperitoneal Chemotherapy
|
Phase 3 | |
Recruiting |
NCT05340569 -
Diagnostic Value of DWI-MRI for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma.
|
N/A | |
Recruiting |
NCT03834272 -
Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT03733184 -
Development of an IDEAL Framework to Standardise Cytoreductive Surgery for Colorectal Peritoneal Metastases
|
||
Recruiting |
NCT06046963 -
Sintilimab in Combination With S-1/Oxaliplatin With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
|
Phase 2 |